Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469235 · ClinicalTrials.gov registry record · Phase 1
Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars
A Phase 1 study, sponsored by Renovo.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00469235 is a Phase 1 study that has completed, run by Renovo. The registered enrollment target is 20 participants.
The verdict
NCT00469235, a Phase 1 study, has completed, sponsored by Renovo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This trial will assess the safety and efficacy of 50 and 200ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe. Ear lobe keloids commonly occur after ear piercing and can be particularly distressing for patients as they are very difficult to conceal and are usually bilateral. As the recurrence rate and growth rate of keloids can vary significantly between individuals, trial subjects will have bilateral ear lobe keloids and will act as their own control. One ear lobe will be treated with Juvista following keloid excision and one with placebo.
Interventions
- DRUG Avotermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469235
The ClinicalTrials.gov registry entry for NCT00469235 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renovo, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avotermin is the first listed.
NCT00469235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00469235 about?
NCT00469235 is a clinical study titled "Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars". This trial will assess the safety and efficacy of 50 and 200ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe. Ear lobe keloids commonly occur after ear piercing and can be particularly distressing for patients as th...
What is the current status of trial NCT00469235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-06. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00469235?
The interventions under investigation include: Avotermin (DRUG).
Who is sponsoring clinical trial NCT00469235?
This trial is sponsored by Renovo, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.